Biogen's (BIIB) EP2653873 Patent is a Positive but Could be Overturned - Morgan Stanley
Tweet Send to a Friend
Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $285.00 price target on Biogen (NASDAQ: BIIB) after management indicated ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
